Ildiko Csiki
Chief Medical Officer Geneos Therapeutics
Seminars
Wednesday 4th February 2026
Utility of ctDNA for Response Assessment of Solid Tumors Treated with Personalized Cancer Immunotherapy
2:20 pm
- Demonstrating how ctDNA identifies molecular response and tracks response duration where MRI-based RECIST lacks clarity
- Leveraging ctDNA alongside imaging to enable earlier and more accurate detection of therapeutic benefit in second-line advanced HCC
- Using ctDNA-guided monitoring as an exploratory endpoint to inform trial design, optimize treatment strategies, and lay the groundwork for broader regulatory acceptance
Wednesday 4th February 2026
Panel Discussion: Clinically Validating Liquid Biopsies for Early Clinical Endpoints to Enhance Patient Selection & Monitoring
3:15 pm
- What evidence and study designs are most critical to clinically validate liquid biopsies as early endpoints in trials, and how do these differ across indications?
- How can validated liquid biopsy endpoints improve patient selection and ongoing monitoring to accelerate therapeutic development and decision-making?
- What regulatory, operational, and data-standardization challenges still need to be addressed to ensure liquid biopsy endpoints are trusted and broadly adopted?
